0001562180-23-000413.txt : 20230113 0001562180-23-000413.hdr.sgml : 20230113 20230113164407 ACCESSION NUMBER: 0001562180-23-000413 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230112 FILED AS OF DATE: 20230113 DATE AS OF CHANGE: 20230113 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Legault Pierre CENTRAL INDEX KEY: 0001391045 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37708 FILM NUMBER: 23529248 MAIL ADDRESS: STREET 1: P.O. BOX 1028 STREET 2: C/O STONE MANAGEMENT LLC CITY: BERWYNE STATE: PA ZIP: 19312 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Syndax Pharmaceuticals Inc CENTRAL INDEX KEY: 0001395937 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 320162505 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 35 GATEHOUSE DRIVE STREET 2: BUILDING D, FLOOR 3 CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 781-419-1400 MAIL ADDRESS: STREET 1: 35 GATEHOUSE DRIVE STREET 2: BUILDING D, FLOOR 3 CITY: WALTHAM STATE: MA ZIP: 02451 4 1 primarydocument.xml PRIMARY DOCUMENT X0306 4 2023-01-12 false 0001395937 Syndax Pharmaceuticals Inc SNDX 0001391045 Legault Pierre C/O SYNDAX PHARMACEUTICALS, INC. 35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3 WALTHAM MA 02451 true false false false Common Stock 2023-01-12 4 M false 24000.00 9.47 A 56000.00 D Common Stock 2023-01-12 4 S false 24000.00 26.7409 D 32000.00 D Common Stock 2023-01-13 4 M false 10000.00 13.58 A 42000.00 D Common Stock 2023-01-13 4 S false 10000.00 27.00 D 32000.00 D Common Stock 2023-01-13 4 M false 5000.00 13.58 A 37000.00 D Common Stock 2023-01-13 4 S false 5000.00 27.00 D 32000.00 D Stock Options (Right to buy) 9.47 2023-01-12 4 M false 24000.00 0.00 D 2030-02-12 Common Stock 24000.00 0.00 D Stock Options (Right to buy) 13.58 2023-01-13 4 M false 10000.00 0.00 D 2027-05-17 Common Stock 10000.00 0.00 D Stock Options (Right to buy) 13.58 2023-01-13 4 M false 5000.00 0.00 D 2027-05-17 Common Stock 5000.00 0.00 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of no options to purchase shares of common stock that are vested and immediately exercisable and there are no options to purchase shares of common stock that have not yet vested. The sale prices ranged from $26.50 to $26.93. This option is fully vested. /s/ Michael A. Metzger, as Attorney-in-Fact 2023-01-13